Printer Friendly

Vitamin B3 may reduce risk of skin cancers.

Nicotinamide (vitamin B3) enhances DNA repair and prevents cutaneous immune suppression after ultraviolet (UV) radiation exposure. It reduces photocarcinogenesis in mice, and human non-melanoma skin cancers (NMSC) in Phase 2 clinical trials. Researchers reported the outcomes of the Phase 3 Oral Nicotinamide to Reduce Actinic Cancer (ONTRAC) Study in the Journal of Clinical Oncology this year.

ONTRAC was a randomized, double-blind, placebo-controlled clinical trial conducted in two tertiary treatment centers in Sydney, Australia from 2012-2014. A total of 386 immune competent participants with > 2 histologically-confirmed NMSC in the past 5 years were randomized (1:1) to oral nicotinamide 500 mg bd (NIC) or matched placebo (PBO) for 12 months.

The primary endpoint was the number of new NMSCs to 12 months. Secondary endpoints included number of squamous cell carcinomas (SCCs), basal cell carcinomas (BCCs), and actinic keratoses (AKs) to 12 months. Skin reviews by dermatologists were performed. The sample size provided 90% power to detect a 33% difference in NMSC rates. Analysis was by intention-to-treat.

The mean age of study population was 66 years, the mean number of NMSC in the past 5 years was 8, and 63% were men. Treatment discontinuation rates were 9% for PBO versus 10% for NIC. 99% of patients underwent at least one post-baseline skin assessment. The average NMSC rate was significantly lower for NIC (1.77) than PBO (2.42). The estimated relative rate reduction (RRR) was 0.23 (95% Cl: 0.04 to 0.38, p = 0.02) adjusting for center and NMSC history, and 0.27 (95% Cl: 0.05 to 0.44; p = 0.02) with no adjustment. Treatment effects of comparable magnitude were found for both BCCs (RRR = 0.20, 95% Cl: -0.06 to 0.39, p = 0.1) and SCCs (RRR = 0.30, 95% Cl: 0 to 0.51, p = 0.05). AK counts were reduced for NIC compared to PBO by 11% at 3 months (p = 0.01), 14% at 6 months (p < 0.001), 20% at 9 months (p < 0.0001) and 13% at 12 months (p < 0.005). There were no clinically relevant differences in adverse event rates between the two arms.

Researchers concluded nicotinamide reduces NMSC formation in high-risk patients and is well tolerated. Furthermore, it is widely accessible as an inexpensive over-the-counter vitamin supplement and presents a new chemopreventive opportunity against NMSCs that is readily translatable into clinical practice.

COPYRIGHT 2015 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:MarketWatch
Publication:Household & Personal Products Industry
Date:Sep 1, 2015
Words:396
Previous Article:Vital surge supplement designed to control cellular aging.
Next Article:L'dara debuts new skin supplement.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters